|By JCN Newswire||
|July 2, 2014 06:46 AM EDT||
In addition to including the ingredients that have long been the foundation of the Chocola BB brand in Japan, such as vitamin B6, nicotinamide, royal jelly and taurine to support consumers' beauty and wellness, Chocola BB Royal Drink also specially contains collagen, L-carnitine, coix seed, polygonatum rhizome and goji berry to specifically address the needs of consumers in China. It also features an easy-to-drink pineapple flavor and is low in calories with approximately 9 kcal per bottle.
In recent years, the healthcare needs of consumers in China have been increasing in line with economic growth. Furthermore, beauty and healthcare related items have been very popular among women in China. In response to these trends, Eisai has launched Chocola BB Royal Drink as the first of its Chocola BB series of products in order to support consumers' beauty and wellness.
Chocola BB Royal Drink is sold through the internet in order to make the product readily accessible to women throughout the country. Following this new product launch to establish a foothold in China, Eisai plans to further introduce its over-the-counter (OTC) products into other countries in Asia.
Since its first product introduction in 1952, the Chocola BB series of products have been widely used by many customers in Japan, Taiwan and Hong Kong as a reliable healthcare brand. In Japan, Eisai has developed a wide range of products including mainstays such as Chocola BB Plus tablets (third-class OTC drug), Chocola BB Royal 2 (designated quasi-drug, drink), Chocola BB Sparkling (food with nutrient function claims, drink) and Bi Chocola (food with nutrient function claims) in response to the diverse needs of consumers.
By marketing the Chocola BB series of products, Eisai is committed to supporting the beauty and wellness of a wider group of consumers in the Asia region, including Japan and China.
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.
Public Relations Department, Eisai Co., Ltd. +81-3-3817-5120
Copyright 2014 JCN Newswire. All rights reserved. www.japancorp.net
Jan. 21, 2017 06:00 AM EST Reads: 2,065
Jan. 21, 2017 05:30 AM EST Reads: 3,549
Jan. 21, 2017 05:00 AM EST Reads: 3,000
Jan. 21, 2017 05:00 AM EST Reads: 4,023
Jan. 21, 2017 03:45 AM EST Reads: 1,985
Jan. 21, 2017 02:30 AM EST Reads: 5,041
Jan. 21, 2017 02:30 AM EST Reads: 6,111
Jan. 21, 2017 02:15 AM EST Reads: 5,359
Jan. 21, 2017 02:00 AM EST Reads: 5,816
Jan. 21, 2017 01:30 AM EST Reads: 6,566
Jan. 21, 2017 01:15 AM EST Reads: 4,904
Jan. 21, 2017 01:15 AM EST Reads: 5,052
Jan. 21, 2017 01:15 AM EST Reads: 2,886
Jan. 21, 2017 12:30 AM EST Reads: 4,578
Jan. 21, 2017 12:15 AM EST Reads: 6,375